This grant supports activities enabling equal access to innovative, sustainable, and high-quality healthcare by reducing adverse drug reactions (ADRs) stemming from the administration of multiple medications (three or more). The objective is to improve patient safety, outcomes, and cost savings through prevention strategies, integration of genetic and biomarker information, and technological innovation in medication management. Results are expected to benefit patients, healthcare professionals, and healthcare systems by decreasing ADRs, guiding clinical and regulatory guidelines, and raising awareness through educational programs.
| Agency | HORIZON (EU) |
|---|---|
| Region | EU |
| Country | N/A |
| Legal form | Company, NGO, Government organization, House union, Private person, Other |
| Start date | 10 Feb 2027 |
| End date | 13 Apr 2027 |
| Max funding | 8,000,000 to 10,000,000 EUR per project |
| Budget | 38,000,000 EUR (2027) |
| Coverage | Projects are expected to provide co-funding as per Horizon Europe rules; typical coverage up to 100% for Research and Innovation Actions, subject to eligibility and cost type. |